ANI Pharmaceuticals Inc (ANIP)
55.86
+0.76
(+1.38%)
USD |
NASDAQ |
Nov 21, 16:00
55.82
-0.04
(-0.07%)
After-Hours: 20:00
ANI Pharmaceuticals Net Income (Quarterly): -24.17M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -24.17M |
| June 30, 2024 | -2.287M |
| March 31, 2024 | 18.21M |
| December 31, 2023 | 1.155M |
| September 30, 2023 | 9.94M |
| June 30, 2023 | 6.245M |
| March 31, 2023 | 1.439M |
| December 31, 2022 | -4.243M |
| September 30, 2022 | -8.60M |
| June 30, 2022 | -14.92M |
| March 31, 2022 | -20.13M |
| December 31, 2021 | -24.14M |
| September 30, 2021 | -4.447M |
| June 30, 2021 | -14.11M |
| March 31, 2021 | 0.086M |
| December 31, 2020 | -3.635M |
| September 30, 2020 | 0.434M |
| June 30, 2020 | -12.34M |
| March 31, 2020 | -7.011M |
| December 31, 2019 | -4.835M |
| September 30, 2019 | 3.895M |
| June 30, 2019 | 6.585M |
| March 31, 2019 | 0.449M |
| December 31, 2018 | 5.43M |
| September 30, 2018 | 5.037M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.777M |
| March 31, 2018 | 2.25M |
| December 31, 2017 | -9.629M |
| September 30, 2017 | 4.72M |
| June 30, 2017 | 2.681M |
| March 31, 2017 | 1.152M |
| December 31, 2016 | -1.08M |
| September 30, 2016 | 2.543M |
| June 30, 2016 | 1.125M |
| March 31, 2016 | 1.346M |
| December 31, 2015 | 2.876M |
| September 30, 2015 | 4.559M |
| June 30, 2015 | 3.571M |
| March 31, 2015 | 4.369M |
| December 31, 2014 | 21.00M |
| September 30, 2014 | 6.746M |
| June 30, 2014 | -2.363M |
| March 31, 2014 | 3.359M |
| December 31, 2013 | 3.432M |
| September 30, 2013 | 1.191M |
| June 30, 2013 | -4.583M |
| March 31, 2013 | -2.291M |
| December 31, 2012 | -3.987M |
| September 30, 2012 | -6.122M |
| June 30, 2012 | -7.344M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-24.17M
Minimum
Sep 2024
18.21M
Maximum
Mar 2024
-5.367M
Average
-4.345M
Median
Net Income (Quarterly) Benchmarks
| Windtree Therapeutics Inc | -12.02M |
| Allogene Therapeutics Inc | -66.29M |
| AIM ImmunoTech Inc | -3.70M |
| Protalix BioTherapeutics Inc | 3.236M |
| Armata Pharmaceuticals Inc | -5.481M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 148.33M |
| Total Expenses (Quarterly) | 168.03M |
| EPS Diluted (Quarterly) | -1.27 |
| Enterprise Value | 1.671B |
| Gross Profit Margin (Quarterly) | 57.48% |
| Profit Margin (Quarterly) | -16.29% |
| Earnings Yield | -1.02% |
| Operating Earnings Yield | 0.89% |
| Normalized Earnings Yield | -1.088 |